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Abstract 
 
 
Dupuytren’s disease is an acquired condition of the hand associated with fibrosis and 
contraction of the fascia of the palm, leading to stiffness and inability to properly flex and 
extend the digits. The disease is caused by both genetic and environmental factors. 
There is some evidence that Angiotensin II (ANGT II) may be associated with this 
disorder and that blockers of ANGT II may help in treating this disease. This study was 
designed to investigate the presence of ANGT II receptors 1 (AT1) and 2 (AT2) in 
myofibroblasts derived from primary tissue of 11 patients who had the disease. My 
hypothesis is that myofibroblasts will express angiotensin receptors and that these will 
primarily be of the AT1 receptor subtype.   
 
Initially, the tissues were excised from patients who where undergoing surgery for 
Dupuytren’s disease in the Department of Plastic Surgery at Royal Preston Hospital. The 
tissue from each patient was dissociated into myofibroblasts using collagenase. The 
myofibroblasts from each patient were cultured in a growth medium over a period of 8-10 
days. The results show that it was possible to obtain successful growth curves for the 
myofibroblast following 8-10 days of cell culture. Some cultures produced better yields 
than others. The myofibroblasts were then stained and treated with specific polyclonal 
antibodies for the identification of AT1 and AT2 receptors. The results show that both 
AT1 and AT2 receptors were presented in myofibroblasts taken from all 11 patients. The 
results show a wider distribution of AT2 receptors compared with AT1 receptors. 
Samples of the myofibroblasts were employed to measure the contractile response and 
intracellular free calcium (Ca2+) concentrations. After numerous attempts using a 
collagen gel model to measure contraction, it was not possible to obtain any successful 
results.  Similarly, fura loaded myofibroblasts show no signs of Ca2+ using a 
microspectoflurometer to measure intracellular calcium. In conclusion, the results 
presented in this thesis have shown that it is possible to isolate tissues from patients with 
Dupuytren’s disease and culture myofibroblasts successfully. Moreover, these 
myofibroblasts contain both AT1 and AT2 receptors. Further experiments are required to 
study the role of blocking AT1 and AT2 receptors excitation-contraction coupling process 
of the myofibroblasts. 
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Dupuytren’s Disease 
 
Dupuytren’s disease (DD) is a multifactorial disorder involving genetic and environmental 
factors. It is a relatively common condition, which causes considerable morbidity 
primarily affecting the hands. DD is a fibrotic disease characterized by nodule formation 
and progressive scarring of the palmar fascia (Gudmundsson et al., 2003). Joint stiffness 
and a loss of full extension develop insidiously over decades (see Figure 1.1). As the 
scarring process progresses, nodules form on the palmar fascia and the finger gradually 
loses its flexibility, with contractures that pull the fingers into flexion at the 
metacarpophalangeal (MP) joint, resulting in significant loss of function (Shaw Jr, et al., 
2007). 
 
 
Figure 1.1: The palmar fascia in normal and Dupuytren’s hands (Taken from Shaw Jr et 
al, 2007). 
 
History 
The earliest reference to DD in medical literature was in 1614, when Plater described 
contractures of the ring and little fingers in a master mason in Basel. Cline described the 
disease in England in 1777 and proposed treatment by fasciotomy. Sir Astley Cooper, 
one of Cline’s students, subsequently delivered lectures regarding the disease in 
London. Alexis Boyer wrote about finger contractures in the early nineteenth century in 
France. One of Boyer’s students referred a patient with finger contracture to the surgeon, 
Guillaume Dupuytren, who operated on the patient and reported the case in a lecture in 
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1831. The lecture was subsequently published in The Lancet in 1834. Dupuytren 
described an association between the disease and manual labour, but more importantly, 
explained the exact anatomical features of the disease and suggested treatment with 
fasciotomy (Gudmundsson et al., 2003). 
 
Aetiology  
DD is associated with diabetes mellitus, seizure disorders and chronic alcoholism. 
Despite many attempts to link DD with work or injury, no study has been conclusive (Liss 
and Stock, 1996). Recent reports have also associated DD with vibration injury (Liss and 
Stock, 1996). Although surgical treatment is routinely carried out with good effect, there 
is a significant rate recurrence (Shaw Jr et al., 2007). The precise mechanisms behind 
the disease are not fully understood. This has been a barrier to discovering an effective 
pharmacological therapy for the condition. 
 
Although not fully understood, the aetiology is probably multi-factorial and has been 
shown to include familial and environmental factors (Burge, 1999). Recent research has 
implicated the myofibroblast cell in the pathogenesis of DD (Rudolph and Vande-Berg, 
1991). This cell has also been shown to be involved in the pathogenesis of other fibro-
proliferative disorders including keloid scarring, breast capsular contractures, myocardial 
infarct scarring, pulmonary fibrosis and renal fibrosis.  
 
The epidemiology of DD is striking. The reported prevalence of DD ranges from 2% to 
42%. This great variability is predominantly affected by ethnicity, age and gender, with 
the highest prevalence being found in men of northern European descent and rising 
steeply after the fourth and fifth decades (Ross, 1999). Men are, on average, six times 
more likely than women to present with the condition (Shaw Jr et al., 2007), with a 
reported male : female ratio ranging between 3.5:1 and 9:1 (Ross, 1999). Dupuytren’s 
diatheses is a term used to describe patients with a strong predilection towards the 
disease (Shaw Jr et al., 2007), who often have bilateral as well as ectopic disease such 
as penile (Peyronie disease) and plantar (Lederhose disease). 
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Genetics 
The genetics of DD are not fully understood. Whilst a genetic influence has been 
mentioned in the literature since 1833 (Burge, 1999), the mode of inheritance has not yet 
been identified. Population studies in England and Norway have confirmed the suspicion 
that DD is more common in these areas (Ross, 1999), but similar studies have not been 
conducted in Asia or Africa, although anecdotal incidence suggests the disease to be 
very uncommon in these areas. Family studies have shown evidence suggestive of an 
autosomal dominant mode of inheritance. This was concluded by Skoog, who analyzed 
a number of studies, including his own (Skoog and Odelberg, 1948), in which they found 
a family history of DD to be present in 22 out of 50 cases. Subsequently, Ling (LING, 
1963) obtained a positive family history in 8 out of 50 patients in Scotland. However, a 
further study has shown 34 of these patients have at least one affected family member. 
Although only 101 of the 832 relatives were affected, of the relatives aged 60 years or 
older, 53% of the men and 33% of the women were affected (Burge, 1999). The 
variation in prevalence, approaching 30% in individuals over the age of 60 in Norway  
(Burge 1999) as well as family clustering is evidence for an autosomal dominant mode of 
inheritance. However, many cases appear sporadically and with no family history. An 
autosomal recessive inheritance or a more complex mode of inheritance has been used 
to explain such cases, although there is no clear evidence for this. At present, although it 
is evident that an inherited susceptibility to DD exists, the condition is considered to be 
multifactorial. It has been suggested that the identification of susceptibility loci would be 
a worthwhile goal in understanding the disease as well is developing new and/or 
preventative treatments (Burge, 1999). 
 
Cellular Level 
The clinically apparent DD nodule is composed of a number of smaller nodules that are 
non-encapsulated but surrounded by connective tissue and collagen bundles, the 
predominant cell being the myofibroblast (Shaw Jr et al., 2007). Early in the disease, the 
cells are spindle shaped. Later, when contracture is apparent, the cells are packed 
closely together and collagen production is evident.  
 
Myofibroblasts exhibit the same morphological characteristics as normal fibroblasts but 
also express  alpha smooth muscle actin (αSMA) microfilaments, which allow them to 
display contractile behaviour (Gabbiani, 1994). Cell-to-cell attachments are also 
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apparent. They are involved in the normal wound healing process, where they produce 
collagen and extracellular matrix components shortly after the inflammatory phase. In 
subsequent remodeling and maturation phases, activated myofibroblasts stimulate 
wound contraction. However, when there is chronic myofibroblast activation, the 
synthesis of new collagen exceeds the rate of collagen degradation, leading to a net 
increase in total collagen as well as an increase in the force and rate of contraction. In 
Dupuytren’s disease this leads to progressive thickening and contracture of the palmar 
fasia, resulting in fixed flexion and loss of function of the hand.  
 
Angiotensin II 
In recent years it has become clear that Angiotensin II (ANGT II), plays not only a role in 
the regulation of body fluids, electrolytes and blood pressure, but also in cell proliferation 
and differentiation as well as local tissue repair and remodeling (Sun and Weber, 1996). 
ANGT II, the biologically active metabolite in the renin-angiotensin system, has been 
identified in many tissues including skin and subcutaneous tissue (Steckelings et al., 
2004). There is now evidence that locally-manufactured ANGT II plays an important role 
in wound healing and fibrosis, with a stimulatory effect on fibroblasts and myofibroblasts 
(Takeda et al., 2004). Importantly, the presence of myofibroblasts containing ANGT II 
receptors has been demonstrated in Dupuytren’s tissue (McKirdy et al., 2001). Several 
studies have demonstrated that angiotensin converting enzyme (ACE) inhibitors can 
reduce the amount of scarring and fibrosis in cardiac and renal animal models. 
Furthermore, in-vitro work has shown an increase in collagen production of cultured 
myofibroblasts with ANGT II, with a subsequent direct inhibitory effect of ACE inhibitors 
on these cells (McKirdy et al., 2001). These observations will form the basis of this study 
exploring the use of ACE inhibitors in Dupuytren’s tissue.  
 
 
The Renin-Angiotensin System (RAS) 
 
The renin-angiotensin system (RAS) has been extensively studied since being identified 
by Tiegerstadt and Bergman in 1898. It has historically been described as a hormonal 
axis, participating significantly in the regulation of fluid and electrolyte balance to 
maintain cardiovascular homeostasis (Campbell, 1987). 
 
The pathophysiological implications of the system have been the focus of much 
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attention, and inhibitors of the RAS such as angiotensin-converting enzyme (ACE) 
inhibitors and angiotensin (ANGT) II receptor blockers have become important clinical 
tools in the treatment of cardiovascular and renal diseases such as hypertension, heart 
failure, and diabetic nephropathy (Paul et al., 2006).  
 
It functions as an unusual endocrine axis in which the active hormone, ANGT II, is 
formed in the extracellular space by sequential proteolytic cleavage of its precursors. 
The secretion of the enzyme renin initiates the pathway, which is activated by several 
stimuli including volume depletion and sodium concentration (Atlas, 2007). 
 
The RAS cascade begins with the synthesis of renin by the juxtaglomerular cells that line 
the afferent arteriole of the renal glomerulus (Barrett 2010). The regulation of renin 
secretion takes place via renal baroreceptor mechanisms, renal NaCl concentration, 
sympathetic nerve stimulation and negative feedback from ANGT II on the 
juxtaglomerular cells. Renin acts by cleaving the precursor angiotensinogen to form the 
biologically inert ANGT I (Paul, 2006)). The primary source of circulation 
angiotensinogen is the liver. ANGT I is rapidly hydrolyzed by the membrane-bound 
angiotensin-converting enzyme to form the biologically active ANGT II (Barrett, 2010). 
 
The multiple actions of the octapeptide ANGT II are mediated by specific receptors on 
the membranes of target cells (Johnston 1990). It is a potent vasoconstrictor, with action 
directly on vascular smooth muscle as well as stimulating the sympathetic nervous 
system, which can also increase heart rate. It acts on cardiac myocytes to increase 
contractility by prolonging the cardiac action potential. It also stimulates the release of 
catecholamines from the adrenal medulla, which can also increase total peripheral 
resistance (Brunton et al., 2005). Other actions on the cardiovascular system include 
hypertrophy of cardiac cells and increased synthesis and degradation of collagen by 
cardiac fibroblasts (Brunton et al., 2005). 
 
As with the cardiovascular system, the effects of ANGT II on the kidney are multifaceted. 
It increases sodium reabsorption via the stimulation of aldosterone release from the 
adrenal cortex as well as via a direct effect on renal tubules. It can also reduce renal 
blood flow by directly constricting the renal vascular smooth muscle and by stimulating 
the central nervous system. This results in markedly decreased renal excretory function 
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(Brunton, 2005). ANGT II also reduces renin secretion through negative feedback.  
 
ANGT II also reduces the sensitivity of the baroreflex in the brain, which potentiates the 
vasopressor effect (Barrett, 2010). 
 
Renin 
  
Renin, a proteolytic enzyme, is synthesised, stored and secreted into the renal arterial 
circulation by the granular juxtaglomerular cells lying in the walls of afferent arterioles 
(Johnston, 1990). Renin is stored in granules within these cells and secreted by 
exocytosis (Friis, 1999). As with many proteins, renin is initially synthesised as an 
inactive precursor molecule that is subsequently converted into the active form. The 
concentration of inactive prorenin in the circulation is approximately tenfold greater than 
the active enzyme (Brunton, 2005). Active renin consists of 2 polypeptide chains linked 
by a disulphide bond. Renin acts only on its specific substrate angiotensinogen to form 
ANGT I, a decapeptide (Johnston, 1990). 
 
Angiotensin Converting Enzyme (ACE) 
 
ACE is a membrane-bound glycoprotein with an apparent molecular weight of 170 kDa. 
It is localized on the plasma membranes of various cell types, including vascular 
endothelial cells, microvillar brush border epithelial cells (e.g., renal proximal tubule 
cells),and neuroepithelial cells (Atlas, 2007). The highest concentration of ACE is on the 
surface of pulmonary endothelial cells (Paul, 2006). ACE is non-specific and cleaves 
dipeptides, including the vasodilator peptides bradykinin and kallidin, to inactive 
metabolites. Thus, functionally, the enzymatic actions of ACE potentially result in 
increased vasoconstriction and decreased vasodilation. Although it is unspecific, ACE is 
the only known enzyme to convert ANGT I into active ANGT II (Dale, 2012). 
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Figure 1.2:  Flow diagram showing the Renin-Angiotensin System  
(Taken from the Clinical Research Competence Centre, University Hospital Erlangen, Germany) 
 
Angiotensin Receptors 
 
The effects of ANGT II are exerted through specific angiotensin receptors The two major 
receptor subtypes are the AT1 and AT2 receptors (Figure 1.2). These have been 
identified using specific angiotensin receptor ligands and cloning these receptors. Most 
of the known biological effects of ANGT II are mediated by the AT1 receptor (Brunton, 
2005). With advent of more sophisticated methods, further analysis of the AT1 receptor 
has identified two specific subtypes - AT1A and AT1B (Sun, 1996a). The AT1A subtype is 
predominant in vascular smooth muscle, lung, heart and hypothalamus tissue whilst the 
AT1B subtype predominates in uterus, adrenal gland and pituitary tissue. Two further 
ANGT II receptors have been proposed (AT3  and AT4), but this is yet to be fully 
understood. 
 
The AT1 receptor is the predominant receptor found in the vascular smooth muscle, 
heart, adrenal cortex, liver, kidney and some regions of the brain and is responsible for 
most of the known functions of the renin–angiotensin system in both physiological and 
pathophysiological conditions (Guimarães, 2005). Importantly, stimulation of AT1 
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receptors by ANGT II has been shown to be influence growth and injury response in 
various organs (Weber, 1999). The AT1 receptor belongs to the G protein-coupled 
receptor family and is coupled to several effector systems involved in cellular growth, 
synthesis and contraction (Guimarães, 2005). 
 
Less is understood regarding the AT2 receptor. This receptor is widely distributed in fetal 
tissues, whereas in adults this distribution is far more restricted (Brunto, 2005). AT2 
receptor is predominant in uterine smooth muscle, ovary, adrenal medulla and some 
brain regions (Guimarães, 2005). Skin, connective tissue and gastrointestinal tissue 
have also been shown to express this receptor, and it appears to have a role in cell 
growth and response to injury. 
 
Evidence is accumulating that AT2 receptors have a significant role in the regulation of 
cardiovascular function, including some studies that suggest AT2 receptors activate a 
vaso-dilatatory pathway, which counteracts the vasoconstrictor action of ANGT II exerted 
through the AT1 receptor (Guimarães, 2005). 
 
Tissue (Local) Renin-Angiotensin System (RAS) 
 
The tradition view of the RAS is that of a classical endocrine system whereby the various 
circulating components result in the delivery of ANGT II to its target organs via the 
bloodstream, producing a physiological response (Brunton, 2005). In addition to the 
circulating RAS, there is much evidence for the ability of tissues such as the brain, 
pituitary, heart and kidney to produce ANGT II (Johnston, 1990; Campbell 1987). 
Numerous studies have also shown that the requisite components of the RAS, such as 
renin, angiotensinogen and ACE are present in such tissues (Dinh, 2001). Furthermore, 
tissue repair has been studied in various organs of the rat including the heart, 
pericardium, skin and kidney. In these tissues ACE and ANGT II binding density was 
measured. High-density ACE and ANGT II binding was shown in areas of fibrosis in 
contrast to non-injured tissue, where binding density was low (Weber, 1997). Using a rat 
model of myocardial infarct, tissue concentration of ANGT II was increased in areas of 
repair. It is now understood that ANGT II plays a significant role in wound healing, 
fibrosis and extracellular matrix homeostasis (Allen 2000). The concept of extracellular 
matrix homeostasis is that fibroblast-derived ANGT II regulates the elaboration of 
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transforming growth factor beta (TGF-β), a cytokine responsible for connective tissue 
formation at normal and pathological sites of collagen turnover (Weber, 1999). Several 
studies have demonstrated a role for ANGT II in tissue fibrosis and wound healing, 
particularly in cardiac infarct tissue (Weber, 1997; Sun, 2000; Sun, 1996a; Sun, 1996b; 
Sun, 1997; Weber, 2000). Such studies identify the myofibroblast to be the key cell 
involved in this process. 
 
ACE Inhibitors 
 
In order to block the effect of ANGT II, one can either prevent the conversion of ANGT I 
to ANGT II or block the AT receptors on which ANGT II acts. ACE inhibitors are highly 
selective drugs suppress the synthesis of ANGT II, although ACE has other substrates 
which may induce parallel effects unrelated to ANGT II levels (ie bradykinin) (Brunton, 
2005). 
 
Many ACE inhibitors have been synthesised. These can be classified into three groups 
based on chemical structure: 
 
 1: sulphydryl-containing ACE inhibitors – structurally related to Captopril 
 2: dicarboxyl-containing ACE inhibitors – structurally related to Elanapril 
 3: phosphorus-containing ACE inhibitors – structurally related to Fosinopril 
 
Several ACE inhibitors are currently available for clinical use, and these differ with 
regard to three properties (Brunton, 2005): 
 
 1: potency 
2: whether AE inhibition is a direct effect of the drug itself or the effect of the 
active metabolite 
3: pharmacokinetics (absorption, half-life, tissue distribution, elimination) 
 
Captopril was the first ACE inhibitor to be marketed. It is a potent ACE inhibitor which, 
given orally, is rapidly absorbed and has a bioavailability of about 75%. Peak plasma 
concentrations occur within 1 hour and it is cleared rapidly with a half-life of 2 hours. As 
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with most ACE inhibitors, it is cleared by the kidneys and excreted mainly in the urine 
(Brunton, 2005). 
 
Enalapril maleate is a prodrug that is hydrolysed by esterases in the liver to produce the 
active dicarboxylic acid, enalaprilat. This is a potent ACE inhibitor that is rapidly 
absorbed with an oral bioavailability of 60%. Peak concentrations occur within 1 hour, 
peaking at 3-4 hours. The plasma half-life is only 11 hours and excretion is primarily 
renal (Brunton, 2005). 
 
Lisinopril a non-sulphur-containing pro-drug. It is the lysine analogue of enalaprilat. In 
vitro, it is a slightly more potent ACE inhibitor that the latter. When taken orally, it is 
absorbed slowly, variably and incompletely (30%). Its plasma half- life is 12 hours and it 
is excreted by the kidney. Lisinopril does not accumulate in tissues (Atlas, 2007). 
 
 
The Extracellular Matrix (ECM) 
 
The extracellular matrix (ECM) is the largest component of normal skin (Schultz, 2005). 
It is this component that gives skin properties such as elasticity, compressibility and 
tensile strength. In acute wounds the provisional wound matrix, containing fibrin and 
fibronectin, acts as a scaffolding to direct cells to the site of injury as well as to stimulate 
cell differentiation and the production of new ECM. The synthesis of ECM is a key 
feature of wound healing. Specifically, ECM is actively involved in both cellular and 
extracellular events that lead to fibrosis (Wight, 2011). The constituents of ECM include 
polysaccharides, water, collagen and proteins. The 2 main classes of ECM molecules 
are fibrous structural proteins and glycosaminoglycans.  
 
Fibrous structural proteins give the ECM strength and they include collagens, elastin, 
laminin. In contrast, proteoglycans consist of multiple glycosaminoglycan chains that 
branch from a linear protein core. These are large, highly hydrated molecules that help 
cushion cells in the ECM (Schultz, 2005).  
 
Collagen is the largest class of fibrous ECM molecule and is responsible for tensile 
strength. There are multiple types of collagen depending on the type and arrangement of 
protein chains; in the dermis collagen is mainly type I and type III. Molecules are rod 
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shaped in a staggered, cross linked side-to-side arrangement (Schultz, 2005). Type IV 
collagen associates with other ECM molecules to form the basement membrane (Brauer, 
1989). 
 
Laminin is a large, cross-shaped molecule which binds Type IV collagen and other 
proteins via integrin receptors. It is therefore a multi-adhesive matrix protein which forms 
bridges between cells and the basement membrane (Frantz, 2010). Elastin is the main 
component of elastic ECM fibres, which consist of adjacent cross-linked elastin 
molecules. This gives certain tissue the ability to recoil following physiological stretch 
(Frantz, 2010).  
 
Fibronectin is a multifunctional glycoprotein with many different binding sites for collagen 
and fibrin molecules, allowing it to link together different components of ECM for cell 
adhesion (Wight, 2011). Also, the binding of fibronectin molecules to certain (integrin) 
cell receptors leads to stimulation of signalling pathways that promote cell attachment, 
migration and differentiation, thus allowing communication between cells and the ECM 
(Schultz, 2005). 
 
Glycosaminoglycans (GAG) are composed of polysaccharide chains and are highly 
negatively charged. This means that they are strongly hydrophilic as they attract 
osmotically active Na+, causing large amounts of water to be drawn into their structure 
(Kim, 2011). As a result, they occupy a huge volume relative to their mass and causes 
turgor, which allows the ECM to withstand compression forces. Hyaluronic acid is a GAG 
found in growing or damaged tissue, which stimulates angiogenesis (Frantz, 2010).  
 
Proteoglycans retain water and form a gel-like substance through which ions, hormones 
and nutrients can move freely. They also appear to have a role in regulating cell 
signalling (Suki, 2008). For example, heparin sulphate chains of proteoglycans bind 
fibroblast growth factors and aid binding of such factors to their receptors. Proteoglycans 
can also bind chemokine molecules such as TGF-β (Schultz, 2005). 
 
TGF-β directly increases fibrosis and scar formation by increasing the expression of 
collagen and fibronectin while reducing the expression of MMPs (matrix 
metalloproteinases) (Leask, 2004). 
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The Process of Wound Healing  
 
The phases of wound healing are overlapping but biologically distinct. These include an 
initial inflammatory phase, which includes haemostasis, removal of devitalised tissue 
and prevention of infection. This is followed by a proliferative phase, where the 
provisional wound matrix is remodelled and replaced by scar tissue. The final phase is 
remodelling, during which tissue maturation occurs and wound strength is maximised 
(Diegelmann, 2004). 
 
Haemostasis and  Inflammatory Phase: 24-48hrs 
 
Initial injury causes endothelial disruption and release of proteolytic enzymes. 
Haemorrhage ensues and a platelet plug adheres to exposed type II collagen following 
haemostatic cascades (Witte, 1997). Within the platelet plug are growth factors (PDGF, 
TGF- α,β) and inflammatory cytokines (fibrinogen, fibronectin, vWF). Initial 
vasoconstriction is followed by vasodilation due to inflammatory mediators (histamine, 
kinins, complement). Vasodilation results in vessel engorgement and plasma exudation 
into the damaged area.  PDGF secreted by platelets during thrombus formation acts as 
a chemo-attractant for macrophages, which remove bacteria and debris. Macrophages 
are also a source of growth factors including TGF-β, which is a chemo-attractant for 
fibroblasts, which migrate into the wound by forming cell-matrix contacts with matrix 
proteins (fibronectin, vitronectin, fibrinogen). The migration of fibroblasts into the wound 
signals the start of the proliferative phase. Growth factors and proteins in the provisional 
wound matrix stimulate fibroblasts to synthesise collagen and extracellular matrix 
components (Li, 2007; Diegelmann, 2004; Witte, 1997a). 
 
Within 12 hours, neutrophils and monocytes migrate to the wound (attracted by PGDF, 
TGF β, complement proteins, fibrin degradation products and leukotrienes). Initially 
neutrophils adhere to the vascular endothelial cell wall releasing elastase and 
collagenase, which allows migration through the basement membrane and into the 
wound matrix where they phagocytose and kill bacteria. The neutrophil response 
declines after a few days. At this stage monocytes are attracted via soluble mediators 
and bind the extracellular matrix via integrin receptors. Here they differentiate into 
macrophages and have 3 main functions (Diegelmann, 2004). 
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• Phagocytosis of bacteria, devitalised tissue and depleted neutrophils 
• Production of collagenase and elastase, facilitating protelytic destruction of 
devitalised tissue 
• Release of soluble mediators (TNF-α, TGF-β, PDGFs, IL-1, IL-6), which recruit 
and activate fibroblasts and promote angiogenesis (Li, 2007). 
 
Proliferative Phase: Day 3 up to 4 weeks 
 
The provisional wound matrix is remodelled and replaced by scar tissue, with 
subsequent increase in the tensile strength of the wound. This consists of collagen, 
proteoglycans and elastin fibres. In order for this to take place, epithelial cells, fibroblasts 
and vascular endothelial cells migrate to and proliferate in the wound site. Fibroblasts 
actively produce collagen and lay down extracellular matrix to strengthen the wound in 
contrast to normal dermal fibroblasts, which are typically sparse and quiescent (Stone, 
2006). 
 
Collagen Production:  Normal dermis contains mainly type I collagen. During early 
wound healing fibroblasts secrete type III collagen, which is replaced by type I collagen 
from week 2 onwards. Collagen synthesis peaks at 5-7 weeks with maximal levels 
present within 6 weeks, although increased synthesis and degradation continue for up to 
1 yr. The early collagen is disorganised and wound tensile strength is poor. Granulation 
tissue consisting of capillary loops and surrounding collagen fibres is formed (Irwin 
1981). 
 
Remodelling Phase 
 
This is the longest phase of wound healing and is believed to last from 21 days up to 1 
year. It commences once the wound defect has been filed with granulation tissue and it 
has been re-epithelialized by migrating keratinocytes.  The precise mechanisms by 
which this takes place are not fully understood but during this period wound contraction, 
collagen remodelling and a progressive decrease in scar vascularity occur (Witte 1997a). 
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During collagen remodelling type III collagen is slowly degraded and replaced by type I 
collagen. There is also increase collagen cross-linking and the tensile strength of the 
wound subsequently increases. Wound contraction is produced by myofibroblasts 
(fibroblasts with actin filaments capable of matrix contraction). 
 
 
The Myofibroblast 
 
Myofibroblasts are specialised cells that share the morphological characteristics of 
fibroblasts and smooth muscle cells (Gabbiani, 1992). Fibroblasts are elongate cells with 
a slender, smooth nucleus, scattered mitochondria, a large Golgi apparatus and 
numerous endoplasmic reticulum. They contain actin microfilaments, but these are 
concentrated beneath the plasma membrane as a meshwork rather than in bundles. In 
contrast, in smooth muscle cells, the actin molecule is organised into bundles that fill 
most of the cell. These bundles are oriented along the long axis of the cell, and the cells 
possess numerous specialised attachment sites. Smooth muscle cells also have a poorly 
developed Golgi apparatus and endoplasmic reticulum (Tomasek, 1999). 
 
Myofibroblasts are large, spindle-shaped cells with nuclear indentations. The cells are 
interconnected and linked to the extracellular matrix through a complex system of 
microfilaments bridging the plasma membrane and extracellular fibronectin. The 
predominant differentiating feature between myofibroblasts and fibroblasts is the 
presence bundles of actin microfilaments, although there are less bundles in 
myofobroblasts than in smooth muscle cells (Tomasek, 1999). The bundles are 
composed of actin, myosin and associated proteins. There are six different recognised 
isoforms of actin, classified according to their pattern of expression as follows: striated 
muscle - two muscle actins (α-skeletal and α-cardiac), smooth muscle – two muscle 
actins (α-smooth muscle actin and γ smooth muscle actin) and every other cell type – 
two non-muscle actins (β-actin and γ-actin). Whist fibroblasts contain only β-actin and γ-
actin, myofibroblasts also express α-smooth muscle actin, although this expression is 
transient (Tomasek, 1999). 
  
The myofibroblast is a key cell for the connective tissue remodeling that takes place 
during wound healing and fibrosis development. In 1971, Gabbiani first described the 
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myofibroblast in the granulation tissue of an open wound using electron microscopy as 
an intermediate cell between the fibroblast and the smooth muscle cell (Gabbiani, 1998).  
The myofibroblast has been identified both in normal tissues, particularly in locations 
where mechanical force is necessary, and in pathological tissues such as hypertrophic 
scarring, fibromatoses and fibrocontractive diseases (Desmoulière, 2005). Initially, it was 
postulated myofibroblasts play a contractile role due to the coincidence of the presence 
of myofibroblasts in such tissues. However, direct proof of the presence and activity of 
contractile elements in these cells was possible through advances in techniques to 
localize and quantify cytoskeletal and contractile proteins (Gabbiani, 1992). It is now 
accepted that fibroblast/myofibroblast transition begins with the appearance of the 
protomyofibroblast, which subsequently differentiates into a myofibroblast with stress 
fibers containing alpha-smooth muscle actin (Desmoulière, 2005). In theory, this allows 
the cell to generate a contractile force. Myofibroblast differentiation is a complex 
process, regulated by TGF β1, an extracellular matrix component (a variant of cellular 
fibronectin), as well as the presence of mechanical tension (Desmoulière, 2005).  
 
Myofibroblast Differentiation  
 
Myofibroblasts have been observed in several types of tissue in addition to granulation 
tissue as originally identified. These include skin, breast, kidney, heart, eye, liver, lung, 
GI tract, bone marrow, joints, uterus and testicle (Klingberg, 2012). The presence of 
myofibroblasts in Dupuytren’s disease tissue has been observed for a considerable 
amount of time (Chiu, 1978), the regulation of which is not yet fully understood. This will 
be addressed in more detail later in this thesis. It is important, however, to understand 
the basic mechanisms behind myofibroblast differentiation in general. 
 
The process of wound healing was described earlier. The initial stage of this process 
involves platelet degranulation, which releases cytokines including platelet-derived 
growth factor (PDGF), epidermal growth factor (EGF) and transforming growth factor β 
(TGF β). PDGF is a chemoattractant for macrophages, which produce fibroblast growth 
factor (FGF) and tumour necrosis factor α (TNF-α). Collectively these cytokines are all 
chemoattractant for fibroblasts, which subsequently migrate to the injured site 
(Klingberg, 2012). It is believed that more specific migration factors are present but this 
is not yet fully understood. 
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TGF-β1 is thought to be an important factor in promoting myofibroblast differentiation. 
One study, where TGF β1 was administrated subcutaneously to rats, resulted in 
myofibroblast-containing granulation tissue formation (Desmoulière, 2005). The cells 
expressed α-smooth muscle actin granules, the formation of which is deemed to be 
synchronous with myofibroblast activation. TGF-β1 was also demonstrated to induce α-
smooth muscle actin expression in quiescent and growing fibroblast populations 
(Desmoulière, 1993).  
 
Myofibroblasts in Wound Healing and Tissue Repair 
 
Myofibroblasts feature in injured or healing tissue such as the kidney, heart and skin. 
These cells play a role in synthesis and contraction of the extracellular matrix. Several 
growth factors are believed to be involved in their differentiation, as well as matrix 
components and mechanical tension (Desmoulière, 2005). One such growth factor, 
transforming growth factor-β1 (TGF-β1), has been shown to influence their conversion. 
TGF-β1 is a ubiquitous polypeptide growth factor thought to have a central role in fibrotic 
conditions (Bisson, 2009). It has been shown to increase collagen deposition in 
granulation tissue myofibroblasts (Gabbiani, 1998) as well as fibroblasts in Dupuytren’s 
disease (Alioto 1994). TGF-β1 expression has also been linked to the rennin-angiotensin 
system (Campbell, 1997). 
 
Both fibroblasts and myofibroblasts have been shown to exhibit AT1 and AT2 receptors 
for ANGT II. As discussed earlier, an increase in ANGT II levels is clearly observed in 
the progression of fibrosis (Sun 1997a). Furthermore, the administration of ANGT II has 
been shown to increase the progression of fibrosis in the rat heart and kidney (Sun 
1993).  
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Tissue culture 
 
Tissue culture is the growth of tissue or a cell separate from the organism or in vitro 
growth in Nutrient medium. This typically facilitated via use of liquid (Growth media), 
semisolid growth media such as broth and agar.   Tissue culture commonly refers to the 
culture of animal cells and tissues. 
In General, there are two types of cell culture 
a. Primary –derived from a living organism. 
b. Cell lines –Stable established cells which proliferate in culture. 
Both types of culture employ similar practical sterile techniques.  
                        
Biological research method in which tissue  fragments (a cell, a population of cells, or all 
or part of an organ) are sustained in an artificial environment for examination and 
manipulation of cell behaviour. 
 
It has been used to study normal and abnormal cell structure biochemical, genetic, and 
reproductive activity; metabolism, functions, and reactions to physical, chemical, and 
biological agents (e.g., drugs, viruses). 
 
 A sample of the tissue is spread on or in a culture medium of biological (e.g., blood 
serum or tissue extract), synthetic, or mixed origin having the appropriate nutrients, 
temperature, and pH for the cells being incubated. The results are observed with a 
microscope, sometimes after treatment (e.g., staining) to highlight particular features.  
 
Work with tissue cultures has helped identify infections, enzyme deficiencies, and 
chromosomal abnormalities, classify brain tumours and formulate and test drugs and 
vaccines. 
 
Cultures have been used to investigate fundamental processes of growth and 
development in both normal and abnormal tissues. One finding has been that normal 
cells undergo an aging process, retaining their ability to multiply readily for only 50 to 
100 generations, after which the rate decreases markedly. This study employed the 
tissue culture technique to grow myofibroblasts. 
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Immunohistochemistry 
 
Immunohistochemistry is the localization of antigens or proteins in tissue sections by the 
use of labelled antibodies as specific reagents through antigen-antibody interactions that 
are visualized by a marker such as fluorescent dye, enzyme, or colloidal gold.  
 
Antibodies 
 
Antibodies belong to a group of proteins called immunoglobulins (Ig). The 
immunoglobulins comprise five major classes (in order of decreasing quantity found in 
plasma): IgG, IgA, IgM, IgD and IgE. Each is composed of two identical heavy chains 
and two identical light chains. IgG and IgM are the most utilised immunoglobulins for 
immunohistochemistry (Atassi et al., 1984). 
 
Polyclonal antibodies are produced by different cells, and in consequence, are 
immunohistochemically dissimilar; they react with various epitopes of the antigen against 
which they are raised. The most frequently used animal for the production of polyclonal 
antibodies is the rabbit. The popularity of rabbits for this purpose is attributed to their 
ease of maintenance (Boenisch, 2001). 
 
Monoclonal antibodies are the product of an individual clone of plasma cells. Antibodies 
from a given clone are immunochemically identical and react with a specific epitope on 
the antigen against which they are raised. Mice are the most commonly used animals for 
the production of monoclonal antibodies (Harboe, 1983). 
 
Direct Method: 
 
The direct staining method is a one- step staining method, and involves a labeled 
antibody (i.e. FITC conjugated antiserum) reacting directly with the antigen in tissue 
sections. This technique utilizes only one antibody and the procedure is short and quick. 
However, it is insensitive due to little signal amplification and is rarely used since the 
introduction of the indirect method. This is the oldest immunostaining technique. 
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Indirect Method: 
 
Indirect method involves an unlabeled primary antibody (first layer), which reacts with 
tissue antigen, and a labeled secondary antibody (second layer), which reacts with 
primary antibody. (Note: The secondary antibody must be against the IgG of the animal 
species in which the primary antibody has been raised). This method is more sensitive 
due to signal amplification through several secondary antibody reactions with different 
antigenic sites on the primary antibody. In addition, since one labeled second layer 
antibody can be used with many first layer antibodies (raised from the same animal 
species) to different antigens.  
 
The second layer antibody can be labeled with a fluorescent dye such as FITC, 
rhodamine or Texas red, and this is called indirect immunofluorescence method. The 
second layer antibody may be labeled with an enzyme such as peroxidase, alkaline 
phosphatase or glucose oxidase, and this is called the indirect immunoenzyme method. 
 
Furthermore, a three-step indirect method utilizes a third andibody layer, which further 
amplifies the signal (Boenisch, 2001).  
 
Calcium (Ca 2+) 
 
Calcium is the most important physiological cation in cellular regulation. It is the trigger, 
the promoter and the regulator and moreover, a ubiquitous intracellular signalling 
molecule which controls a wide range of cellular processes including secretion, 
membrane transport, contraction, cell proliferation, gene transcription and even cell 
death. In un-stimulated cells, the free intracellular calcium concentration [Ca2+]i is 
between 50–100 nM. In order to maintain this low resting level, a variety of pumps and 
uptake systems are present in the plasma membrane and in intracellular organelles to 
buffer (Ca2+). Calcium mobilisation is dependent upon intracellular calcium stores as well 
as extracellular calcium medium [Ca2+]o. An increase in cellular calcium originates from 
two major sources: 
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a. The release of Ca2+ from intracellular stores (ER), which is rapid. Calcium release 
from the ER after IP3 generation is crucial for exocytosis. Similarly the release of   
Ca 2+ from SR is crucial in muscle contraction. 
b. The influx of Ca2+ from extracellular source with the aid of IP3 by the depletion of 
an intracellular pool. 
 
Both of these mechanisms give rise to high-localised (Ca2+) signals. Many agonists can 
promote an influx of Ca2+ from the extracellular medium by the following processes: 
 
a. Opening of voltage-operated Ca2+ channels 
b. Phosphorylation of Ca2+ channel proteins by cAMP and cGMP. 
c. Receptor-operated Ca2+ channels in which modulation of channel activity 
does not involve cytosolic signal molecules but a direct control by receptor 
channel coupling G- proteins. 
  
 
Working hypothesis: Angiotensin receptors may be involved in the aetiology and 
development of Dupuytren’s disease and ACE inhibitors may play a role in the 
pharmacological treatment of the disease. 
 
Main Aim: The main aim of this study was to isolate and culture myofibroblasts from 
primary tissues from patients who have Dupuytren’s disease and to investigate the role 
of angiotensin receptors in the development and treatment of the disease. 
  
Specific aims: 
 
1. To undertake a thorough literature review in the area. 
2. To isolate the tissues from patients and to culture them into myofibroblasts. 
3. To study the morphology of the myofibroblasts and to undertake 
immunohistochemical staining for the presence and distribution of angiotensin receptors. 
4. To study the contraction of the myofibroblasts using a collagen gel system 
5. To measure intracellular free calcium concentration [Ca2+]i in the myofibroblasts using 
fura-2 loaded cells. 
 6. To analyse the data and write up the MSc by research 
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Materials 
 
Patients:    Eleven patients from Royal Preston Hospital 
Tissues:      Isolated skin tissues from all 11 patients 
Reagents:  Trypsin, collagenase 
Antibodies: Anti-AT1 receptor antibody produced in rabbit (Anti-AGTR1, Sigma 
Aldrich) 
Anti-AT2 receptor antibody produced in rabbit (Anti-AGTR2, Sigma 
Aldrich) and  
Anti-Actin, α-Smooth Muscle antibody produced in mouse (Sigma Aldrich 
A5228). 
 
Culture media: DMEM, foetal calf serum, Ham’s F10 
 
Chemicals:  Analar grade chemicals, DMSO 
Immunohistochemistry: Vectastain® Universal Elite ABC Kit 
Drugs:   Angiotensin II 
Lisinopril  
Penicillin  
Streptomycin 
Amphotericin 
Glutamine  
[Val5]-Angiotensin II acetate salt hydrate  
Irbesartan  
S-(+)-PD 123177 trifluoroacetate salt hydrate 
1-Methylhydantoin  
 
 
Methods 
 
Tissue Harvesting 
 
Patients who were scheduled for surgery to remove Dupuytren’s tissue were identified 
on the waiting list at Royal Preston Hospital. Verbal and written information was provided 
to patients at least one day prior to surgery (see Appendix). Consent to use tissue for 
research was obtained from LREC (see Appendix) and tissue specimens were 
transferred from operating room to the hospital cell culture laboratory in the collection 
medium. Each patient gave written consent to use their tissue for research (see 
Appendix). 
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Cell Culture 
 
Dupuytren’s tissues were isolated and then stored in collection medium at 4°C for up to 
48 hours after harvest. The biopsy was transferred to a Petri dish along with fresh 
collection medium (Dulbecco’s Modified Eagle Medium, Penicillin, Streptomycin, 
Amphotericin). Using a sterile forceps and scalpel, any obvious non-Dupuytren’s tissue 
was removed. The tissue was then transferred to a fresh Petri dish and macerated into 
approximately 1mm x 1mm fragments using a scalpel. 
 
The fragments were then transferred into a universal container with 10-15 ml of 
collection medium, allowing the larger pieces to settle and discarding the supernatant. 
The fragments were then re-suspended in a centrifuge tube with 10 ml complete growth 
medium (Dulbecco’s Modified Eagle Medium, L-Glutamine solution, Ham’s F10, foetal 
calf serum). 1 ml of collagenase solution (Collagenase type 1a, Hank’s Balanced Salt 
Solution) was added and the tubes were left to incubate at 37°C for up to 12 hours, or 
when disaggregation was near completion. The solution was pipetted several times to 
aid further disaggregation and then centrifuged for 5 min at 1500 RPM). The supernatant 
was removed and the cells were re-suspended in 10 ml complete growth medium and 
centrifuged again. The supernatant was discarded again and the cells were re-
suspended in 10 ml complete growth medium, transferred to a 75cm2 cell culture flask 
and incubated at 37°C. After 72 hours, the medium was discarded and cells were fed 
with complete growth medium and returned to the incubator. Cultures were examined 
twice per week thereafter. 
 
Passaging Cell Cultures 
 
When cultures reached confluence, spent medium was aspirated and the cells were 
washed with 10 ml of Hank’s Balanced Salt Solution. This process was repeated twice in 
order to flush away any remaining medium. A volume of 1 ml of 0.25% Trypsin/EDTA 
was then pipetted into the flask and the flask was incubated for 5-10 minutes until cell 
detachment was observed under an inverted microscope. A volume of 2 ml of complete 
growth medium was added to inactivate the Trypsin and the solution was pipetted to re-
suspend the cells prior to freezing, counting or further experiments. 
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Cell Counting 
 
Haemocytometer method: 
 
An aliquot of 50 µl of cell suspension was pipetted into a micro-centrifuge tube. A 
coverslip was placed over the chambers of the haemocytometer and 20 µl of cell 
suspension was slowly pipetted against the short side of the coverslip so that the 
suspension was drawn into the chambers. The haemocytometer was placed onto the 
stage of an inverted phase contrast microscope and the middle 25 squares of one 
chamber (centre grid, 1 mm2) were viewed. The number of cells in these 25 squares was 
counted and the same process was repeated for the other chamber. The average 
number of cells in the centre grid was calculated and multiplied by 104 to calculate the 
number of cells per 1ml of suspension. This number was multiplied by the total volume of 
cell suspension in ml to calculate the total number of cells. 
 
Coulter Counter Method: 
 
The Coulter Counter was flushed using Isoton II diluent. The particle size was set to 10 
µm and a background count was performed using diluent only.  A volume of 100 µl of 
cell suspension was then pipetted into an Accuvette II vial and 10 ml of Isoton II diluent 
was added. Each suspension was counted 3 times and an average cell count was 
calculated from this. 
 
 
Cell Freezing 
 
The cell suspension was pipetted into a centrifuge tube and centrifuged at 1500 RPM 
from 5 min. The supernatant was aspirated and the cells were re-suspended at a 
concentration of 1 x 106 per 500 µl complete growth medium containing 10% Foetal Calf 
Serum (FCS). The same volume for dimethyl sulfoxide (DMSO, cryoprotectant) with FCS 
was added drop wise to the cell suspension, shaking the solution gently after each drop. 
The suspension was then transferred into cryovials in 1 ml aliquots. The cryovials were 
then placed in a 1oC freezing container (Mr Frosty Cryo). The container was placed in a 
–70oC freezer for 24 hours and  then transferred into a liquid nitrogen refrigerator. 
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To revive the cells, the cryovials were placed into a 37°C water bath for 1-2 min. Cells 
were then pipetted aseptically into a centrifuge tube containing transport medium and 
centrifuged at 1500 RPM for 5 min. The supernatant was aspirated and cells were re-
suspended in 1-2 ml of complete growth medium. The cells were then transferred  
to culture flasks containing10 ml of complete growth medium and incubated at 37oC. 
Following cell attachment, medium was aspirated and replaced with fresh complete 
growth medium to remove any residual DMSO. 
 
Fixation and Immunostaining of Cell Monolayers 
 
A. Tris Buffered Saline (TBS) 
 
Distilled water 
Trizma Salt 
Sodium Chloride 
Bovine Serum Albumin 
 
B. Primary Antibodies 
 
Anti-AT1 receptor antibody produced in rabbit (Anti-AGTR1, Sigma Aldrich) 
Anti-AT2 receptor antibody produced in rabbit (Anti-AGTR2, Sigma Aldrich) 
Anti-Actin, α-Smooth Muscle antibody produced in mouse (Sigma Aldrich A5228) 
 
 
C. Vectastain Universal Elite ABC Kit 
 
E. Diaminobenzidene Solution (DAB) 
 
 
Procedure 
 
Glass coverslips were placed into a sterile Petri dish and covered with 10 ml of Complete 
Growth Medium. A volume of 100 µl of cell suspension was pipetted over each coverslip 
and allowed to grow to 50-60% confluence. 
 
The medium was aspirated from the Petri dish and the monolayers washed 3 times with 
TBS. The cells were covered with a 1:1 ratio of methanol to acetone pre-chilled to -20oC 
and placed rapidly into a -20oC freezer to fix for 10 minutes. The fixative was then 
removed from the Petri dish and the cells were allowed to air dry.  
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When ready for staining, the cells were carefully rehydrated with TBS. An aliquot of 40 µl 
of primary antibody was pipetted onto each coverslip and incubated in the closed Petri 
dish for 30 min at room temperature. The cells were then rinsed twice with TBS.  A 
volume of 40 µl of secondary antibody was then pipetted onto each coverslip and 
incubated in the closed petridish for 30 min at room temperature. The cells were then 
rinsed twice with TBS.  An alquot of 40 µl of streptABComplex/HRP solution was 
pipetted onto each coverslip and incubated in the closed petridish for 30 min at room 
temperature. The cells were rinsed twice with TBS. Finally, DAB solution was pipetted 
onto each slide and incubated for 5 min before rinsing twice with distilled water. 
 
Cells were counterstained by pipetting Harris’s haematoxylin into the petri dish for 15 
seconds. The haematoxylin was then removed and the nuclei blued by rinsing several 
times with warm tap water. The cells were serially dehydrated by rinsing with graded 
alcohol solutions. Each coverslip was dipped in Xylene and mounted in styrolite onto 
glass slides. 
 
Fixation and Immunostaining of Frozen Sections and Paraffin Sections 
 
Frozen sections and paraffin sections were cut from harvested tissue, which was either 
collected fresh or placed in formalin. This was performed by an experienced hospital 
laboratory technician. Once mounted on coverslips, the immune-staining process 
followed the same method as outlined above.  
 
Collagen Gel Contraction (Colgen 2006)  
 
Collagen from rat tail (Sigma Aldrich C7661) 
1M Sodium hydroxide (NaOH) 
Glacial acetic acid 99.9% 
24-well cell culture plates 
0.22 µm syringe-driven filter units 
 
 
Preparation of Collagen for Use in Collagen Gels 
 
Acetic acid solution (0.2%) was made from 99.9% glacial acetic acid and water. The 
solution was sterilized using the syringe-driven filter unit and cooled to 4°. Under sterile 
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conditions, the rat tail collagen was mixed with 0.2% acetic acid to a concentration of 6 
mg/ml of collagen solution. The solution was placed on a motorised stirrer at 4°`C for 2-5 
days until the collagen was completely dissolved in solution. The solution was the diluted 
with sterilized water to a concentration of 3 mg/ml and 0.1% acetic acid. The solution 
was placed on a motorised stirrer at 4°`C for one further day and subsequently stored at 
4°`C.  
 
pH (NaOH) Titration of Collagen 
 
 A volume 400 µl of DMEM was pipetted into each of 8 Eppendorf tubes. Thereafter, a 
volume of 0.2ml of prepared collagen solution (3 mg/ml) was added to the first 
Eppendorf tube and 1 µl of 1 M NaOH was pipetted into the same tube. The mixture was 
pipetted up and down 3 times. The resulting collagen concentration was 1 mg/ml. The 
process was repeated in the remaining 7 Eppendorf tubes using increasing amounts of 
NaOH (2-7 µl). The rigidity and colour of the gels with different volumes of NaOH were 
compared in order to determine the volume of NaOH that produced the most rigid gel 
with a neutral pH.  
 
Preparing Cells Before Suspension in Collagen Gels 
 
A. Complete Growth Medium 
 
B. Experimental variables 
 
[Val5]-Angiotensin II acetate salt hydrate (AT1 receptor agonist - A2900 SIGMA) 
Irbesartan (AT1 antagonist - I2286 SIGMA) 
S-(+)-PD 123177 trifluoroacetate salt hydrate (Selective AT2 receptor antagonist - 
P5749 SIGMA) 
1-Methylhydantoin (AT2 receptor agonist - M49887 ALDRICH) 
Lisinopril (ACE Inhibitor - L2777 SIGMA) 
 
A confluent layer of myofibroblasts was detached from the culture flask by aspirating 
spent medium and pipetting 1 ml of 0.25% Trypsin/EDTA solution. The cells were then 
centrifuged and re-suspended in complete growth medium. Cells were then counted 
using the Coulter Counter. The remaining suspension was centrifuged and the 
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supernatant removed. Fresh complete growth medium was added (+/- experimental 
variable) in order to reach a final concentration of 1.5 x 105 cells/ml following the addition 
of the collagen solution. 
 
Pouring Cell Populated Collagen Gels 
 
Collagen gels were prepared under sterile conditions as outlined above. A volume of 660 
µl of cell suspension (+/- experimental variable) was added to a sterile tube. A volume of 
330 µl of 3 mg/ml collagen solution was added to the tube and the appropriate volume of 
1 M NaOH was also added quickly. The solution was mixed up and down with a pipette 
and 500 µl of the mixture transferred to a 1.9 cm3 well. The gels were left to solidify at 
room temperature for 20 min. An equal volume of complete growth media (+/- 
experimental variable) was the added to each well. The gel was dissociated from its 
mold by gently running the tip of a 200 µl pipette around the rim of each well. The well 
plate was returned to the incubator at 37°C 
 
Measurement of contraction 
 
A digital camera (Canon Ixus 8.0 Megapixel) was used for image acquisition every six 
hours following solidification of cell-populated collagen gels. 6-well plates containing  
cell-populated collagen gels were placed on a portable lightbox and photographs were 
taken at standardised 40 cm above the laboratory worktop. The images were digitally 
uploaded using ImageJ Software Version 1.32 (downloaded from National Institutes of 
Health, Bethesda, MD). The surface area of each image was calculated using this 
software and the measured contraction relative to time presented in numerical and 
graphical form. 
 
Measurement of intracellular free calcium [Ca2+]i using a fluorescence micro plate 
reader 
 
Measurement of [Ca2+]i was performed as previously described in the literature 
(Robinson et al., 2004). The measurement of [Ca2+]i was performed by seeding a density 
of 10,000 cells/well in black 96 well plates (Griner, UK) in 100 µl of growth medium. At 
sub confluence, the cell culture medium was then replaced with FBS free medium for 24 
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hr in order to synchronize cells into a non-proliferation stage. The cell were then loaded 
with 20 µl 25 µM Fura-2  acetoxylmethyl ester (AM) in cell medium at 37°C for 30 min 
followed by 30 min at temperature to minimize dye leakage and sequestration into 
intracellular organelles. After loading, the cells were washed 2-3 times with 200 µl of 
Hank’s Buffered Salt Solution (HBSS) to remove excess fluorescent dye. The cells were 
then treated with  angiotensin x min in a calcium free medium. The cells were washed 
twice with 200 µl HBSS and then a volume of 100 µl HBSS /wells was added to each 
well. The same procedure was carried out for the untreated cells. The intensity of the 
fluorescence’s of Fura-2 AM was measured at emission wavelengths of 340 nm. The 
relative changes in calcium concentration using Fura-2 AM were determined by 
calculations of 
                                    [[Ca 2+ ]i = Kd β (f – f min) / (f max – f).         
Kd, the Ca-Fura-2 dissociation constant, β the fluorescence intensity ratio, excited at 380 
nm without and with Ca; f min and f max (Robinson et al., 2004). All values were 
expressed as ratio units of the Fura-2 AM fluorescent intensity (Robinson 2004). 
Note that the above experiments were only carried out once and they were 
unsuccessful. 
 
Statistical Analysis 
 
All control and test data collected from the different experiments were analysed using 
Statistical Package for Social Sciences (SPSS) version 17, Student’s – t test and 
ANOVA test. Data obtained were expressed as mean ± standard deviation (S.D) where 
possible. Each experiment was repeated for 3-6 times where possible. A value of (p < 
0.05) was taken as significant. 
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Patients and Epidemiology 
 
All patients were recruited from the Department of Plastic Surgery at Royal Preston 
Hospital. This study recruited 11 patients who had attended for surgical treatment of 
Dupuytren’s. All patients gave written consent to be included in the study. The indication 
for surgery for all patients was that the disease was restricting their hand function. The 
degree of restricted function was varied, but in all cases there was a significant 
deficiency in their ability to perform at least one activity of daily living. As such, these 
patients had to undergo surgery. The results presented in this thesis are based on 11 
patients (9 males, 2 females) between the ages of 48 to 79 (mean=62.4) who underwent 
surgery for Dupuytren’s disease at Royal Preston Hospital during the period of the study 
and who consented to their tissues being used for research. Figure 3.1 shows the age 
distribution of the 11 patients who were included in this study. The results show that 
there is a relatively wide variation in age, but that all patients were middle age or older. 
 
 
Figure 3.1: Bar chart showing age of patients 
 
Figure 3.2 (below) shows the proportion of manual workers to non-manual workers in the 
11 patients. The patients’ occupations varied greatly, but 5 of out 11 patients (45%) were 
manual workers including builders and mechanics. The remaining 55% of the patients 
had non-manual jobs including teachers, solicitors and other professionals. Please note 
that these figures are referring to the main occupation of the patients until the time of 
retirement, as several of the patients were retired at the time of the study. 
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Figure 3.2: Pie chart showing the percentage of manual non-manual workers in this 
study 
 
Dupuytren’s disease is associated with a number of risk factors. The results presented in 
Figure 3.3 show that all patients exhibited at least one risk factor or condition associated 
with Dupuytren’s disease. The most common of these was a Northern European 
background. The results presented below also show that certain patients in this study 
also suffered with diabetes, epilepsy and alcohol abuse. Furthermore, 3 patients were 
smokers and 2 patients had suffered previous hand trauma.  
 
 
Figure 3.3: Bar chart showing patients’ risk factors for Dupuytren’s disease 
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Figure 3.4 shows the proportion of patients who had a positive family history of 
Dupuytren’s disease among the 11 patients employed in this study. The results show 
that of 4 out of 11 patients (36.4%) had a positive family history of Dupuytren’s disease. 
 
 
Figure 3.4: Pie chart showing family history of Dupuytren’s disease.  
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Myofibroblast Cell Culture 
 
Tissues were harvested from all 11 patients over a 4-month period. They were 
dissociated using collagenase and cultured for 4-5 months. Figures 3.5-3.14 show the 
cell specimens from patients 1-10. The results presented in these figures show that 
these are large, spindle-shaped cells with nuclear indentations and a branching structure 
with numerous long cytoplasmic connections. Note that these cells can resemble normal 
fibroblasts, but that immunostaining for α-SMA was subsequently performed to confirm 
that the cell were in fact myofibroblasts. 
 
 
Figure 3.5: Specimen 1  
(scale bar 200 µm, 100x magnification) 
 
Figure 3.6: Specimen 2 
 
Figure 3.7: Specimen 3 
 
Figure 3.8: Specimen 4 
!
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Figure 3.9: Specimen 5 
 
Figure 3.10: Specimen 6 
 
Figure 3.11: Specimen 7 
 
Figure 3.12: Specimen 8 
 
Figure 3.13: Specimen 9 
 
Figure 3.14: Specimen 10 
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Growth curves 
 
Figure 3.15 shows data of a typical growth curve for myofibroblasts obtained from 
patient number 2. The results show that these myofibroblasts can grow in a time-
dependant manner from day 1 to day 10. There was slow growth from day 1 to day 4, 
followed by a rapid growth from day 5 to day 7 and then reaching an almost plateau level 
between day 7 and day 10. 
 
 
 
Figure 3.15: Typical growth curve for Dupuytren’s myofibroblasts (specimen 2, passage 
5) in 25cm3 culture flasks over a period of 10 days. 
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Figure 3.16 shows the growth curve for myofibroblasts obtained from patient number 10. 
Again, that data show a slow growth for day 1 to day 4, following by a rapid growth for 
day 5 to day 7, reaching maximum growth within days 8-10. 
 
 
 
Figure 3.16: Typical growth curve for Dupuytren’s myofibroblasts (specimen 10, 
passage 4) in 25cm3 culture flasks over a period of 10 days. 
 
 
 
Immunostaining 
 
 
Figures 3.17-3.23 show typical micrographs of immunostaining for AT1, AT2 and α-
SMA. This was performed on cell monolayers, paraffin sections and also on frozen 
sections.  
 
Cell monolayers 
 
All cell monolayers were negative for the antibodies tested. This was tested using 
varying concentrations of primary antibody as well as incubation periods ranging from 30 
min to 24 hours. 
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Paraffin sections 
 
Using paraffin sections, all specimens showed positive staining for α-SMA, as well as 
the kidney control section used (Figure 3.17, 3.18). However all specimens, on paraffin 
section, stained negatively for AT1 and AT2 receptors (Figure 3.19, 3.20). This was 
tested using varying concentrations of primary antibody as well as incubation periods 
ranging from 30 min to 24 hours. 
 
Using frozen sections, only 1 out of 5 specimens stained mildly positively (specimen 6) 
for AT1 receptors whilst the remainder of specimens stained negatively for AT1 
receptors (Figure 3.21. 3.22). However, all frozen sections stained positively for AT2 
receptors (Figure 3.23). 
 
 
Figure 3.17: Micrograph showing kidney paraffin section stained for alpha smooth 
muscle actin (α-SMA). This micrograph is typical of 3 different experiments on similar 
tissues. 20x magnification. 
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Figure 3.18: Micrograph showing Dupuytren’s specimen 6, paraffin section stained for 
α-SMA. This is typical of 6 such different experiments on different specimens. 10x 
magnification. 
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Figure 3.19: Micrograph showing a paraffin section stained for AT1 receptors in 
myofibroblasts from patient number 5. This is a negative result and it is typical of 20 such 
different experiments at different primary antibody concentrations as well as different 
incubation periods. 10x magnification. 
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Figure 3.20: Micrograph showing a paraffin section stained for AT2 receptors in 
myofibroblasts from patient number 5. This is a negative result and it is typical of 20 such 
different experiments at different primary antibody concentrations as well as different 
incubation periods. 10x magnification. 
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Figure 3.21: Micrograph showing a frozen section stained for AT1 receptors in 
myofibroblasts from Dupuytren’s patient number 6. This is a mildly positive result. Note 
that 12 such different experiments at different primary antibody concentrations as well as 
different incubation periods were carried out on other specimens, all of which were 
negative for AT1 receptors. 6x magnification. 
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Figure 3.22: Micrograph showing a paraffin section stained for AT1 receptors in 
myofibroblasts from patient number 6. This is a negative result and it is typical of 12 such 
different experiments at different primary antibody concentrations as well as different 
incubation periods. 4x magnification. 
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Figure 3.23: A typical micrograph showing a frozen section obtained from Dupuytren’s 
specimen 6, stained for AT2 receptors. This is a positive result and extensive staining 
can be observed throughout the tissue section. This is typical of 9 such different 
experiments. 20x magnification. 
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Discussion 
 
This study was designed to investigate the condition of Dupuytren’s disease and this 
discussion will focus on the disease itself, its aetiology, causes, diagnosis and treatment. 
It will also describe the role of angiotensin in the development of the disease, the 
isolation of the tissues and myofiboblasts, growth of the myofibroblasts using tissue 
culture techniques, and the identification of angiotensin receptors in the myofibroblasts. 
In addition, the discussion will also touch on the problems and issues involved in this 
type of study. 
 
Dupuytren’s disease is a common condition affecting 4-6% of Caucasians worldwide 
(Hurst 2009). The severity of the disease is variable, but it is progressive, and can often 
lead to extreme restrictions in the function of the hand of affected patients. The disease 
is thought be multifactorial, but the causative factors are not yet fully understood. 
Dupuytren’s disease has been associated with several conditions such as diabetes 
mellitus, alcohol abuse, epilepsy, smoking, manual labour and vibration injury (ShawJr, 
2007). There is also a genetic component, and the highest prevalence is found on men 
of European descent (Ross, 1999). The genetics of the disease are not fully understood 
and the mode of inheritance is yet to be established. Also several studies have shown a 
strong familial link, many cases appear sporadically  (Skoog, 1948; Burge, 1999; Ling, 
1963). 
  
Since the description of the disease by Dupuytren in 1831, the macroscopic pathology 
has been understood to involve contraction, or shortening of the palmar fascia (ShawJr, 
2007). Experiments conducted in the 1950s suggested that cells were responsible for 
tissue contracture (Tomasek, 1999). The cells responsible were later shown to be the 
myofibroblasts (Gabbiani, 1992). The morphological features of the myofibroblast are a 
combination of those of smooth muscle cells and fibroblasts, and it is thought that these 
cells can create contractile force, thus propagating the contraction of the palmar fascia in 
Dupuytren’s disease. The feature that distinguishes myofibroblasts from smooth muscle 
cells and fibroblasts is the presence of bundles of actin microfilaments arranged along 
the long axis of the cell (Tomasek, 1999). Specifically, these microfilaments contain α-
smooth muscle actin, which we have successfully identified in this study (Skalli, 1989). 
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Surgical intervention is usually considered and it is based on the degree of contraction 
across the metacarpophlangeal and proximal interphalangeal joints. In general, more 
than 30 degrees of flexion in the former or ay flexion deformity of the latter would warrant 
intervention. The disease is progressive and therefore surgery will not cure the affected 
patients. Surgery is therefore offered to patients with contractures that cause a 
significant loss of function or difficulty with self-care. Earlier operative treatment is 
considered in certain circumstances, such as in patients with rapidly progressive 
disease. Surgery is relatively contraindicated in patients with very minimal restriction of 
function or in those whose major concern is cosmetic rather than functional. Surgery is 
not offered to patients with a general medical condition that places them at unreasonable 
risk of severe complications. There are several surgical methods of resecting the 
diseased tissue, a detailed description of which is beyond the scope of this discussion. 
However, all surgical options carry similar risks, including bleeding, nerve damage, 
artery damage, necrosis of skin, failure to correct the deformity and complex regional 
pain syndrome (Janis, 2007). Although many non-surgical treatments have been 
previously employed, such as radiotherapy, ultrasound, interferons and steroids, none 
have been proven to have consistent success (Janis 2007). One of the most 
encouraging developments in non-surgical treatment of Dupuytren’s disease is 
collagenase enzymatic fasciotomy, in which the enzyme collagenase is injected into 
diseased tissue causing lysis of diseased cords. However, structures such as tendons 
and nerves, which lie in close proximity and are also composed of type I collagen, are 
also susceptible to injury from collagenase (Shaw Jr, 2007). It is therefore technically 
challenging to ensure that normal structures are not damaged with this therapy, and 
clearly a more selective therapy would be favourable. 
 
Thus, the treatment of Dupuytren’s disease is fraught with difficulties. All treatment 
modalities have subject to a high risk of disease recurrence (ShawJr, 2007). This reflects 
the fact that the disease pathology on a cellular level is not fully understood. It is 
therefore important to investigate this debilitating condition in further detail in order to 
develop a potential therapy. As described, the myofibroblast is the key cell involved in 
Dupuytren’s disease. Chronic fibroblast activation leads to excessive collagen synthesis 
and contraction. A full appreciation of the cellular mechanisms which activate the 
myofibroblast to function in this manner is required in order to develop a therapy that can 
specifically target the myofibroblast and reduce its fibrotic and contractile activity. 
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In this thesis, the role of Angiotensin II in relation to Dupuytren’s disease has been 
investigated. The Renin-Angiotensin (RAS) has long been understood to play a 
circulating hormonal role in fluid and electrolyte balance and blood pressure control 
(Johnston, 1990). However, there is much evidence showing ANGT II to play a local role 
in wound healing, fibrous tissue formation and regulation of the extracellular matrix, 
particular in cardiac and renal models (Sun, 1997a; Weber, 1997; Sun 1996; Sun, 2000; 
Sun, 1993; Sun, 1997). It is thought that ANGT II is generated at the site of injury. For 
example, ANGT II concentration is greater in scar tissue following myocardial infarction 
compared to normal myocardium (Yamagishi, 1993).  ANGT II has also been implicated 
in renal tubule-interstitial fibrosis associated with ureteric obstruction (Klahr, 1995; 
Weber, 1997). Numerous studies have shown the requisite components of the RAS, 
such as renin, angiotensin and ACE, are present in tissues such as the brain, heart and 
kidney (Dinh, 2001). In the rat heart and kidney, it has also been shown that ACE and 
Angt II binding was of high density in areas of fibrosis compared to non-injured areas 
(Weber, 1997).  
 
Studies of fibrosis in kidney (Mizuno, 1998) and lung fibroblasts (Nguyen, 1994) have 
shown a reduction in the population of fibroblasts and myofibroblasts in culture when 
treated with ACE inhibitors. The use of ACE inhibitors as an anti-fibrotic agent in patents 
with renal and cardiac disease is now widely established in clinical practice. However, 
the role of ANGT II in the skin and subcutaneous tissue has been investigated in less 
detail.  
 
Acceleration in dermal tissue healing with the application of ANGT II has been 
demonstrated in the rat excisional wound model (Rodgers, 19970. Furthermore, the ACE 
inhibitor Lisinopril has been shown to inhibit the rate of wound contraction and collagen 
deposition in the rat model (Mckirdy, 2001).  
 
The presence of Angiotensin receptors in Dupuytren’s disease has been previously 
investigated, revealing AT1 receptors in myofibroblasts cultured from tissues excised 
from 5 different patients with Dupuytren’s disease (Mckirdy, 2001), which was a strong 
basis for the methods employed in this study. 
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In the present study, tissues were harvested from 11 patients undergoing surgery for 
Dupuytren’s disease in the Department of Plastic Surgery at Royal Preston Hospital. 
These tissues were treated with collagenase to aid the dissociation into cells, which were 
successfully cultured. The growth curves obtained in the present study are comparable 
to those of fibroblasts as published previously (Takashima, 2001). The cells were 
cultured for a total period of 6-8 months, although some cell lines became susceptible to 
infection, particularly in the early stages of the study when this technique was initially 
being learnt. 
 
Morphologically, the myofibroblasts can resemble fibroblasts in that they are large, 
spindle-shaped, branching cells. There are certain features that can differentiate 
myofibroblasts from fibroblasts, such as irregular, stellate cellular outlines with numerous 
long cytoplasmic connections connected by intermediate or adherence junctions. 
Moreover, they are connected to the extracellular matrix by cell-to-stroma attachment 
sites through fibronexus. They contain bundles of cytoplasmic filaments arranged 
parallel to the long axis of the cell, a well-developed rough endoplasmic reticulum, golgi 
and indented nucleus with prominent nucleoli (Ravikanth, 2011). Many of these features 
can be observed with electron microscopy. However, a striking histological feature 
differentiating myofibroblasts from fibroblasts is the presence of bundles of actin 
microfilaments, and more specifically, the expression of ∝-smooth muscle actin (∝-SMA) 
(Tomasek 1999). For this reason, the tissues harvested in this study were tested for the 
presence of ∝-SMA using the Immunostaining technique described. The results show 
that the tissues were strongly positive for ∝-SMA, confirming that the cells present were 
myofibroblasts. 
 
In contrast to the work conducted by McKirdy et al (2001), which showed Dupuytren’s 
tissue to stain strongly positive for AT1 receptors, the present study has found that the 
tissues stained only mildly positively for AT1 receptors at best, with some specimens 
showing no signs of AT1 receptors. Exhaustive attempts were made to establish the 
presence of AT1 receptors, including numerous concentrations of primary antibody and 
various incubation times. It is noteworthy that this study was larger in that tissues from a 
larger number of patients were used. 
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In addition, this study has shown that tissues obtained from the eleven patients who had 
Dupuytren’s disease stained positively in an extensive manner for AT2 receptors in all 
patients. This positive staining was far more readily observed than that for AT1 receptors 
on the first attempts, without the need to modify the incubation periods or concentrations 
of primary antibody. This observation suggests that the expression of AT2 receptors is 
more prominent than the expression of AT1 receptors in Dupuytren’s disease. This is a 
new discovery, which has not been found on other studies. 
 
Although both AT1 and AT2 receptors have been identified in a variety of organs, much 
less is known about the role of AT2 receptors compared to AT1 receptors. It is apparent 
that AT1 receptors are responsible for mediating all the well-now stimulatory actions of 
ANGT II on blood pressure, electrolyte homeostasis (Timmermans, 1999). AT2 receptors 
have been identified in several tissues including the brain, adrenal gland and heart (Allen 
2000), and are more widely distributed in fetal tissues than in adults (Brunton, 2005), It is 
now known that AT2 receptors mediate anti-growth and apoptotic actions of ANGT II, 
and there is a growing body of evidence that the stimulation of AT2 receptors may offset 
or oppose the AT1 receptor-mediated actions of ANGT II on cell growth (Gallinat, 2000). 
In the brain, the administration of an AT2 receptor antagonist has been shown to 
potentiate the stimulatory effects of ANGT II on drinking behavior and vasopressin 
secretion, demonstrating an opposing effect of AT2 receptor stimulation to AT1 (Höhle, 
1996). In chronic heart failure, AT2 up-regulation occurs in fibroblasts and is associated 
with down-regulation of AT1 receptors (Gallinat, 2000). Opposing actions of AT1 and 
AT2 receptors have also been demonstrated in the kidney. Furthermore, AT2 receptor 
expression in the heart and it has been shown to increase substantially following 
myocardial infarction (Gallinat, 2000). It therefore seems apparent that AT2 receptors 
play a significant role in tissue repair in a variety of organs (Gallinat 2000). Importantly, 
the presence of AT2 receptors has been identified in the skin (Viswanathan 1992). 
Furthermore, an experimental wound healing model in the skin of young rats has shown 
that ANGT II receptor expression and this is enhanced during experimental wound 
healing, and that the major proportion of this increase was due to AT2 receptors 
(Viswanathan, 1992). 
 
One of the main aims of this study was to investigate the effects of ACE inhibitors in 
Dupuytren’s disease. This was based on the previous discovery of the presence of AT1 
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receptors in these tissues. It was hypothesized that ACE inhibitors would exhibit anti-
fibrotic effects via blockade of AT1 receptors. The identification of AT2 receptors in this 
study leads  a new direction because of the existing evidence of opposing actions of AT1 
and AT2 receptors as described above. As discussed, the role of AT2 receptors is much 
less understood than AT1 receptors. It would therefore be appropriate to investigate not 
only the effects of ACE inhibitors and AT1 receptor antagonists, but also the effects of 
AT2 agonists and antagonists in Dupuytren’s disease. 
 
Numerous attempts were made in this study to generate a three-dimensional collagen 
gel model in order to measure the effect of various agents on the contraction of 
myofibroblasts. Whilst a clear protocol was followed precisely, the method could not be 
carried out successfully because the collagen gel did not solidify following the addition of 
the cell suspension, despite the fact that the addition of NaOH was titrated to the nearest 
µl. Therefore, this study attempted to modify the protocol with reference to other collagen 
gel contraction studies. However, none of these actions resulted in the ability to produce 
a cell-populated collagen gel that would solidify in order to enable measurements of 
contraction. This part of the study had to be abandoned due to time restriction. However, 
in future studies, it may be preferable to employ a commercially available gel contraction 
assay kit. 
 
 
Concluding remarks 
 
Together, this study has shown that it is possible to obtain primary tissues from patients 
with Dupuytren’s disease and culture the tissues successfully into myofibrobasts over 
time. It is also possible to stain for the AT1 and the AT2 receptors on the myofibroblast 
plasma membrane. Unfortunately, because of difficulties it was not possible to measure 
contraction and intracellular free calcium concentrations in the myofibroblast in the 
absence and presence of angiotensin and its receptor antagonists. Nevertheless, the 
study has led to the discovery of AT2 receptors in Dupuytren’s disease, which can be 
the basis of further studies. The study has also led to the development, understanding 
and learning new physiological techniques, which are required for the MSc by Research.  
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Conclusion 
 
This study employed primary tissues isolated from the hands of eleven patients who 
suffered with Dupuytren’s disease, which is caused by both genetic and environmental 
factors. There is some evidence that Angiotensin II (ANGT II) may be associated with 
this disorder and that blockers of ANGT II may help in treating this disease. This study 
was designed to investigate the presence of ANGT II receptors 1 (AT1) and 2 (AT2) in 
myofibroblasts derived from primary tissue of 11 patients who had the disease. The 
tissue from each patient was dissociated into myofibroblasts, employing the enzyme 
collagenase. Myofibroblasts from each patient was successfully cultured over a period of 
8-10 days to produce normal growth curves. Following culture, myofibroblasts were 
studied morphologically and they were subsequently stained and treated with specific 
antibodies for the identification of AT1 and AT2 type angiotensin receptors. The results 
show the distribution of both AT1 and AT2 receptors. The results suggest that more AT2 
receptors were observed in the cells compared to AT1 receptors. However, the relative 
abundance of these receptors cannot be verified by immunohistochemistry because 
there may be a difference in affinities of the respective primary polyclonal antibodies 
employed. Numerous attempts were made to measure both contraction and intracellular 
free calcium concentration in the myofibroblasts but without any successful results. The 
present results clearly show that it is possible to harvest myofibroblasts from tissues of 
patients who have Dupuytren’s disease and that these myofibroblasts can be used 
successfully to identify AT1 and AT2 receptors. With time, it may be possible to study the 
process of excitation-contraction coupling in the myofibroblasts. 
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Scope for Future Studies 
 
Future studies may involve the following: 
 
1. It is possible to measure contraction in the myofibroblasts using different physiological 
methods in the literature. A video edge system in conjunction with three-dimensional 
collagen gel can be used to measure contraction. The cells can either be electrically 
stimulated, or different drugs and their respective antagonists can be employed, 
particularly the specific agonists and antagonists of both AT1 and AT2 receptors, which 
have been observed in the present study. The contractile response to these agents may 
give information relating to the clinical response of myofibroblasts in Dupuytren’s tissue 
in vivo. Extracellular calcium can also be varied in some experiments to determine the 
calcium dependency of contraction. 
 
2. It is possible to investigate the role of cytosolic calcium in the process of contraction in 
the myofibroblast. Cells will be loaded with Fura 2 and intracellular free calcium 
concentrations [Ca2+]i measured using a micro-spectoflurometer. The myofibroblast can 
be stimulated electrically or with drugs, hormones and angiotensin in the absence and 
presence of their respective antagonists.  
 
3. In addition to measuring physical contractility, it may be possible to investigate the 
levels of such cations as sodium, potassium, magnesium, calcium, zinc, copper, iron and 
selenium in the presence and absence of angiotensin stimulation. Both flame 
photometry and ICPMS can be used to measure the ions.  
 
4. It is also possible to study the morphology of the primary tissues and the 
myofibroblasts using phase contrast and electro-microscopy.  
 
5. It is also possible to employ binding studies to identify angiotensin receptors in the 
tissues and cells using radio-labelled angiotensin, which may give more information 
relating to the relative abundance of AT1 and AT2 receptors compared to the 
immunohistochemistry methods used in the present study. 
 
 
60 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
THE EFFECTS OF ACE-INHIBITORS (ANTI-FIBROTIC DRUGS) ON 
DUPUYTREN’S DISEASE. 
 
You are being invited to take part in a research study. Before you make a decision on 
whether you would like to participate it is important for you to understand why the 
research is being done and what it will involve.  
 
Please take time to read the following information carefully and discuss it with others 
if you wish. Also please ask us or your clinician if there is anything that is not clear or if 
you would like more information. Take time to decide whether or not you wish to take 
part. Keep this information sheet for future reference. Thank you for reading. 
 
What is the purpose of the study? 
 
Dupuytren’s disease is extremely difficult to either prevent or resolve. Treatment of 
Dupuytren’s disease usually requires surgical removal as there are currently no oral 
treatments for this condition. 
 
Angiotensin-Converting Enzyme (ACE)-Inhibitors are drugs commonly used in renal and 
cardiovascular disease to reduce scarring and fibrosis. Our study aims to determine 
whether ACE-inhibitors can also be beneficial to reduce scarring and fibrosis in 
Dupuytren’s disease. 
 
We are asking for patients to donate scar tissue from their routine surgery for removal of 
Dupuytren’s disease for research to test the effects if ACE-inhibitors on the scarring the 
process. NO extra tissue will be taken for the study, only tissue which would be removed 
as part of your routine surgery would be used. NO tissue will be stored and any tissue not 
used will be disposed of according to hospital policies. The study may provide the basis 
for a safe therapy for patients with Dupuytren’s disease. 
 
Do I have to take part? 
 
It is entirely your decision whether or not to participate. If you do decide to take part you 
will be given this information sheet to keep and will be asked to sign a consent form (you 
will also be given a copy of the signed consent form to keep). You are still free to 
withdraw at any time without giving a reason. A decision not to take part or a decision to 
withdraw at any time will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
 
Taking part in the study will not alter you routine surgery in any way. You WILL NOT 
be required to have any extra hospital visits or have any extra investigations. The study 
only involves tests on the samples being donated.  
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What is being tested? 
 
Angiotensin-Converting Enzyme (ACE)-Inhibitors such as Enalapril are drugs 
commonly used in renal and cardiovascular disease to reduce scarring and fibrosis.  
Our study aims to determine whether ACE-inhibitors can also be beneficial to reduce 
scarring and fibrosis in Dupuytren’s disease. 
 
What are the disadvantages or risks associated with taking part? 
 
There are NO disadvantages or risks specifically associated with taking part in the study. 
The associated risks of your routine surgery will have been discussed separately with you 
by your consultant. 
 
What are the possible benefits of taking part? 
 
There is no clinical benefit from taking part in the study and it will not affect the outcome 
of your surgery. 
The study endeavors to develop a drug therapy for the treatment for Dupuytren’s disease. 
 
Will my taking part in the study be kept confidential? 
 
All information which may be collected will be kept strictly confidential. Any 
information about you which leaved the hospital will have your name, age, address and 
all identifiable information (including patient/hospital/NHS number) removed so that you 
cannot be recognised from it. 
 
What will happen to the results of the study? 
 
The results of the study will be submitted for publication in scientific journals. You may 
receive information about the results of the study upon request. 
 
 
Who has reviewed the study? 
 
The study has been reviewed by the Lancashire Teaching Hospitals Trust Ethics 
Committee. 
 
Contact for further information: 
 
Dr Christopher Stephen 
Tel: 01772 716565 (Royal Preston Hospital) 
Email: Christopher.Stephen@lthtr.nhs.uk 
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Dupuytren’s Disease Study Consent Form 
 
Researchers: Mr C Stephen Dr L Touil Mr SW McKirdy Prof J Singh  
 
Please read carefully before initialing each statement and finally signing and dating the bottom 
 
I …………………………can confirm that I have received, read and understood the 
information sheet for the Effects of ACE Inhibitors in Dupuytren’s Disease Study 
(V1/Aug 09). I have been given the opportunity to discuss the study with anyone I wish, 
including the researchers, prior to giving my consent. I have been given the opportunity 
to have my questions answered.  
 
Initials….. 
 
I understand that my participation is entirely voluntary and I am free to withdraw my 
consent at any point without explanation without affecting my medical care or legal 
rights.  
 
Initials…..  
 
I give permission for access to my medical notes by responsible individuals from 
Lancashire Teaching Hospitals NHS Foundation Trust or regulatory authorities in 
connection with this study.  
 
Initials….. 
 
I agree to participate in the Use of ACE Inhibitors in Dupuytren’s Disease Study. 
 
Initials….. 
________________________________________________________________________ 
 
 
 
--------------------------    ------------------  ------------- 
Name of Patient     Signature    Date  
Block Capitals          
 
--------------------------    ------------------  ------------- 
Name of Person taking consent   Signature    Date  
Block Capitals 
 
--------------------------    ------------------  ------------- 
Name of Researcher     Signature    Date  
Block Capitals  
 
1 copy to patient and 1 copy to researcher  
Original to be placed in notes  
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